The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend broader access to several peptides, including BPC-157, despite FDA staff recommendations against their inclusion on the Section 503A Bulks List. While the committee’s recommendations are nonbinding and do not immediately change what may be legally compounded, they mark a significant development in the ongoing debate over peptide regulation and could influence the FDA’s next steps.
In an article by the Financial Times, Edgar Asebey explained that the committee’s recommendations could provide political support for future action by HHS leadership, even if it differs from the FDA’s scientific recommendations. Edgar noted that the FDA has historically followed its own scientists’ recommendations, making the committee’s vote a notable departure from past practice and one that stakeholders across the peptide industry should continue to monitor.
